



ANNUAL REVIEW

July 2021 - June 2022

**MIND MEDICINE AUSTRALIA IS SUPPORTING THE DEVELOPMENT OF
PSYCHEDELIC-ASSISTED PSYCHOTHERAPY IN AUSTRALIA AS TREATMENTS
FOR KEY CLASSES OF MENTAL ILLNESS WITHIN OUR HEALTH SYSTEM**

Level 1, 10 Dorcas Street
South Melbourne VIC 3205
Australia

CONTACT

Phone: (03) 8679 6015
Email: hello@mindmedicineaustralia.org
www.mindmedicineaustralia.org

Fast Facts..... 3

A Message From Our Chair and Executive Director..... 4

Our Board..... 10

Our Vision..... 11

What is Psychedelic-Assisted Psychotherapy?..... 12

Our TGA Application..... 14

Our Events..... 15

International Summit..... 16

Neuromedicines Discovery Centre..... 18

Our Local Chapters..... 20

Our Volunteers..... 22

Our Book..... 23

The Mind Medicine Institute (MMI)..... 24

Our People..... 26

With Thanks..... 29

Corporate Governance..... 30

Financial Report..... 31

"The psychedelic experiences themselves were the most profound healing experiences of my life and relieved me of the burden of pain, terror and shame I had been carrying." - S. Ball

- Around the world psychedelic-assisted therapies are on the cusp of **widespread acceptance** as a breakthrough therapy for key classes of mental illness.
- These medicines have been shown to be **very safe and non-addictive when used in a medically controlled environment**.
- These therapies are being trialed as treatments for **depression, PTSD, anxiety, end-of-life distress, dementia, anorexia and eating disorders, opioid, alcohol and smoking addictions** and a number of other illnesses.
- These treatments are showing **high remission rates** (as high as 80% in some trials) after just 2-3 medicinal doses in combination with psychotherapy.
- There have been **over 160+ current or completed psychedelic trials** in the past decade.
- In the 50's/60's these medicines were considered **the next big breakthrough in treatments for mental illnesses** before the War on Drugs in 1970, which stopped further research for decades.
- Both psilocybin-assisted psychotherapy for major and treatment-resistant depression as well as MDMA-assisted psychotherapy for PTSD have been granted **"Breakthrough Therapy Designation" by the Food and Drug Administration (FDA)** in the USA to fast-track the approval process because clinical evidence to date indicates that they may demonstrate substantial improvement over currently available therapies.

A MESSAGE FROM OUR CHAIR AND EXECUTIVE DIRECTOR

In our first three and half years we have made remarkable progress in growing public awareness of Psychedelic-Assisted Therapy in Australia. We are seeing a paradigm shift in the curiosity, acceptance, and interest into the use of psilocybin and MDMA assisted therapy for depression, addiction, PTSD, obsessive-compulsive disorder, anorexia, cognitive decline, end-of-life stress, and other mental and physical illnesses in our communities.

Our goal is to build the ecosystem for these treatments in Australia and ensure they are accessible to all who need them in medically controlled environments. Please see our key strategic objectives below.

Four Key Strategic Areas

Awareness and Knowledge Building

- Education & events, including free webinar series
- Major International Medical Summit (Nov 2021)
- State & regional chapters
- Awareness campaigns

Access to Medically Approved Therapy

- Preferred legal & ethical frameworks
- Psychological support services
- Medicine Rescheduling, Sourcing & Protocols
- Rollout strategy



Professional Development Program

- Mind Medicine Institute (MMI) established to further develop educational and training courses
- Includes the part-time professional Certificate in Psychedelic-Assisted Therapies course for health practitioners (now in its 2nd year) as well as shorter courses and workshops

Engagement with University Sector and Novel Research

- Establishment of Neuromedicines Discovery Centre at Monash University
- Engagement with other universities to promote research, development and economic analysis and rollout plans
- Promoting & funding relevant research

Our focus is wholly clinical.

What we have achieved in three and half years with your support:

Awareness and Knowledge Building

- **200+ webinars, screenings and special events** attracting **41,000+ participants**
- **Launch of free online Global Webinar Series** where World-leading experts provide illuminating presentations and conversations about the ground-breaking opportunity psychedelic-assisted therapies offer
- Launch of **Mind Medicine Australia Podcast series**
- **Over 550,000+ visits** to the Mind Medicine Australia website

- **Over 39,000+ followers** on our social media channels
- **Over 500,000+ views** on our YouTube Channel
- **6000+ visits to our e-book** about psychedelic-assisted psychotherapies
- **Over 35,000+ people in our database** incl. over 15,000 health professionals and over 1000 psychiatrists
- **500+ regular donors**
- **200+ media appearances**
- **33+ local Chapters** around Australia and New Zealand with **2200+ members** and growing
- **55,000+ views to our TGA How-to guide** during the 2022 public submission period
- **Video animation** explaining the mental illness epidemic in Australia and the benefits of psilocybin and MDMA-assisted psychotherapy with **80,000+ views**
- **Created a short documentary, Science vs Stigma**, to dispel some of the myths associated with these important medicines with over **28,000+ views**
- **Over 150,000+ views of Shroom Boom**, a light-hearted music video
- **Implemented a Board Observership program** in conjunction with VMIAC.
- **Appointed as member of peak body, Mental Health Australia**
- **Launch of MMA online shop** selling a range of unique merchandise including Australia's first book of Psychedelic Healing Stories
- **Initiated Australia's first Essential Research poll** to gauge the sentiment of the Australian public on the issue of access to psychedelic medicines in medically controlled environments as treatments for key classes of mental illness. **67% agreed that 'People experiencing terminal illness should have the choice to use psychedelic-assisted therapy to ease end of life distress'.**

- Presented and produced Mind Medicine Australia's inaugural **International Summit on Psychedelic Therapies for Mental Illness in November 2021**
- **Nearly 1,000 people registered for our two-day workshop and Global Summit** from every state of Australia and more than 15 other nations
- **Over 90,000 views** of our Summit sizzle reel
- **Over 80,000 visits** to the Summit website
- **Over 5000 queries received** from the Summit website

- **110 virtual breakout rooms**
- **32 global leaders** in the field presented on a range of topics
- **19 major Corporate partners**
- **Over 160 Education partners**
- **17 Supplier Partners**
- **15 Media Partners**
- **8 Scholarship winners**
- **5 Poster winners**
- 1 global 4-day event with massive impact

Access to Medically Approved Therapy

- **Further submissions made to the TGA to reschedule MDMA and psilocybin** from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines)
- **Australia's TGA has granted approvals through SAS-B for psilocybin and MDMA** assisted therapies for patients on a case-by-case basis
- **Continued review and lobbying of Federal and State legislative and regulatory requirements** to permit the medicines for clinical use to treatment resistant patients
- **Granted an Innovation Patent** over an improved method of synthesis of MDMA
- Successfully **procured medical grade GMP standard psychedelic medicines for import to Australia** for use in trials
- Developing a **gold standard National Care Program, clinical protocols and standard operating practices** for psychedelic-assisted therapies in partnership with leading clinical groups around Australia
- Key **university student placement partnerships** with University of Melbourne

Professional Development Program

- Our highly anticipated **Certificate in Psychedelic-Assisted Therapies** commenced in January 2021 featuring a world class Faculty. We have been thrilled to welcome **260 therapists including GPs, physicians, psychiatrists, psychologists, psychotherapists, mental health nurses, social workers, occupational therapists, addiction specialists, paramedics and counsellors.**
- Confirmed **world-leading facilitators** for our Certificate in Psychedelic-Assisted Therapies (CPAT) professional development course
- **Described as “the best course of its kind in the world”** by Prof. David Nutt on ABC Radio National interview (UK)
- **Over 500+ applications** received since launch
- **Over \$200,000 raised for CPAT grants** through philanthropy to support those in regional and rural areas and therapists suffering financial hardship. Over 50 grants have been awarded so far.
- **Over 127,000+ views** of the CPAT sizzle reel
- **Mind Medicine Institute (MMI)** established to further develop educational and training courses
- Launch of the **Fundamentals in Psychedelic-Assisted Therapies Course** with over 320+ participants so far
- **Recognition by key peak/membership bodies** of our professional development and training programs

Engagement with University Sector and Novel Research

- **Successfully advocated for \$15 million to support innovative mental health clinical trials** utilising psychedelic-assisted therapies from the Federal Government through the Medical Research Futures Fund
- Launch of The Monash University **Neuromedicines Discovery Centre**, follows a proposal by MMA and developed over a 2-year period
- **17+ current trials** of psilocybin, MDMA, LSD and Ibogaine in Australia and New Zealand, compared to just one trial when Mind Medicine Australia was launched.
- Developed a **BLOG**, significant education resources and partnered with Universities to disseminate these as well as sharing these via our website
- Discussions with key University stakeholders continue

Noteworthy from Media Releases:

- **TGA Expert Review Findings Support the Therapeutic Use of Medicinal Psychedelics** in Treating Mental Health Crisis in October 2021
- **Mind Medicine Institute Launched as a Dedicated Training, Education and Clinical Services Organisation** Focusing on Psychedelic Assisted Therapies for Mental Illness and the Developing Understanding of the Mind, Cognition and Human Consciousness in October
- Mind Medicine Australia **Launched Australia's First Book of Psychedelic Healing Stories** in October 2021
- Monash University announced the **establishment of the Neuromedicines Discovery Centre** to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness in November 2021
- Mind Medicine Australia hosted Australia's Inaugural **International Summit on Psychedelic Therapies for Mental Illness** online in November 2021
- Mind Medicine Australia **joined a global coalition launched to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances** in January 2022
- **New Polling** by Mind Medicine Australia **Revealed Over 60% of Australians Support Increased Access to Psychedelic Medicines** in February 2022
- Mind Medicine Australia Lodged **New Applications for the Restricted Medical use of MDMA and Psilocybin Assisted Therapies** for Patients with Treatment Resistant Mental Illnesses in March 2022. The full applications can be found [here](#).

The progress we are making in public education was exemplified in several headline media articles including in the Australian Financial Review, The Australian, The Age, Herald Sun, The Saturday Paper and Vogue Australia and media interviews including with Channel Nine, Channel 10, The Project, ABC and numerous other TV and radio stations and online media.

Our primary focus over the next couple of years will be on psilocybin-assisted psychotherapy and MDMA-assisted psychotherapy, given their **"Breakthrough Therapy Designation"** with the Food and Drug Administration ("FDA") in the United States and the strong clinical evidence that supports both their effectiveness and safety. We are also interested in developing other medicinal therapies to treat a variety of conditions.

Behind the scenes, we are working closely with key stakeholders to ensure that **these therapies will be accessible and affordable to all Australians needing these treatments in medically controlled environments**, so that cost and geography doesn't become a barrier.

In the last 18 months, we have assembled a comprehensive **leadership team** with expertise in mental illness, non-profit development, business practices and networks, public health, events, marketing and educational development.

Mind Medicine Australia is also supported by an outstanding **Board, Ambassadors** and an **Advisory Panel of over 70 local and international experts** in medicine, psychiatry, psychology, pharmacology, research, science more broadly, ethics, law, policy, anthropology, business and therapeutic practices. We have also developed a Lived Experience and Young Leaders Panel.

As we move through 2022, our vision and capacity continue to grow, as does the need to make these effective and safe therapies a legally available treatment through our medical system for the **increasing number of individuals suffering** as a result of the pandemic, environmental challenges and global trends which challenge social cohesiveness and social inclusion.


We ask for your continued and expanded support to overcome the roadblocks and the naysayers, so that we can fund the path for psilocybin and MDMA assisted psychotherapy to help treat the millions experiencing key mental illnesses in Australia. This is personal for every one of us.

As Carl Jung said, "The sole purpose of human existence is to kindle a light in the darkness of mere being."

With gratitude for your interest and generosity. There has never been a more important time to support innovation in the treatment of mental illness.



Peter Hunt AM
Chair



Tania de Jong AM
Executive Director

OUR BOARD



Peter Hunt AM
CHAIR

Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women's Community Shelters



Tania de Jong AM
DEPUTY CHAIR

Co-founder Mind Medicine Australia, Founder Creative Universe, Creativity Australia The Song Room, Umbrella Foundation & Creative Innovation Global



Admiral Chris Barrie AC
DIRECTOR

Chairman, Fearless - PTSD-Australia New Zealand; Former Chief of the Australian Defence Force



Professor Jane Burns
DIRECTOR

Chair of Open Arms, Chair of STREAT and Chair of the Centre for Mental Health, Swinburne University



Dr Eli Kotler
DIRECTOR

Medical Director at Malvern Private Hospital, Consultant Psychiatrist, Addiction and Trauma expert



Dr Simon Longstaff AO
DIRECTOR

Executive Director at the Ethics Centre



Monojit (Mono) Ray
DIRECTOR

CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia



Hon Andrew Robb AO
DIRECTOR

Australia's Minister for Trade and Investment (2013-2016); Chair of Asia Link



Nicholas Smedley
DIRECTOR

Chairman, Respi Limited

OUR VISION

Mind Medicine Australia exists to help alleviate the suffering and suicides caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We will develop safe and effective psychedelic-assisted treatments to treat a range of mental illnesses.

Mind Medicine Australia is a registered charity founded by **Tania de Jong AM** and **Peter Hunt AM**. We are supporting clinical research and working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We connect and educate medical practitioners, consumers, academia, government, industry, regulatory bodies, philanthropists, investors and other stakeholders.

Mind Medicine Australia is currently focused specifically on the clinical application of **medicinal psilocybin** and **medicinal MDMA** for certain mental illnesses. Our focus is wholly clinical.



MIND MEDICINE
A U S T R A L I A



Our Team


INTRODUCTION TO PSYCHEDELIC ASSISTED PSYCHOTHERAPY

Psychedelic-assisted therapy typically involves **‘talk-therapy’ alongside the ingestion of a psychedelic such as psilocybin or MDMA**. Researchers and clinicians often describe three distinct therapy phases:

- 1. Preparation
- 2. The acute psychedelic experience
- 3. Integration

The non-psychedelic elements of this approach are essential for both **effectiveness and safety**.

These 3 phases are illustrated in the timeline below.



Various approaches to preparation have been developed, from diet to psychotherapy. In clinical trials, participants will typically attend a number of talk-therapy sessions with a trained therapist who will be in attendance during the psychedelic session. A therapeutic alliance is developed during this time, and the nature of the individual’s struggle is explored.


During the psychedelic session, **‘set’ and ‘setting’ are considered paramount**. ‘Set’ refers to mind-set, a complex mix of more transient phenomena like expectation and mood, and more enduring phenomena like personality and past experience. ‘Setting’ refers to the context or environment in which the session takes place, including basic factors like the comfort and aesthetic quality of the room, and more complex factors like the quality of the relationship with the clinicians and the mood they help to set. Whilst many modern clinical trials occur within hospitals or research institutes, the **session rooms are made to appear as comfortable living rooms**. There are typically **two therapists in attendance**.

The patient can sit or lie on a couch, is often encouraged to wear eyeshades, and sometimes listen to a carefully-selected playlist of music. Oral ingestion of a capsule of synthesised psychedelic compound (e.g., psilocybin) is the most common route of administration, and the session will typically last for about 8 hours.

A common therapeutic approach during psychedelic sessions is to be non-directive: attentive but usually silent, supporting the emerging process, offering assistance and guidance if needed, listening and responding to the patient when they speak, with little analysis of the material. In some trials, a single high-dose psychedelic session occurs; in others, there are two or three high-dose sessions. Many trials are also **placebo-controlled**, wherein the patient will usually have one placebo session – sometimes a very low dose of the psychedelic, sometimes an ‘active placebo’ that produces some noticeable somatic effects – in addition to their high-dose session(s).

Immediately after the psychedelic session and in the following days, a process of **integration** is facilitated by the therapist. During these conversations, the patient has the opportunity to process, make sense of, and give meaningful expression to their psychedelic experience.

Psychedelic-assisted therapies have shown strong clinical results. **Medicinal psilocybin and medicinal MDMA are very safe to use in a medically controlled environment and are non-addictive**. Whilst MMA is focused on the medicinal use of psilocybin and MDMA, it should be noted that contrary to some assertions these are also amongst the safest recreational drugs.



Source: Nutt, D and Castle, D, et al. (2019) The Australian drug harms ranking study, Journal of Psychopharmacology, Vol 33, Issue 7

OUR TGA APPLICATION

On 30 September 2021, the Therapeutic Goods Administration (TGA) published the findings of the **Independent Panel Review** which confirmed that research supported the conclusion that these medicines were safe and well tolerated by patients when given in a medically controlled environment and produced statistically significant results. These findings confirm the advice that we have previously received from our own experts which formed the basis of our rescheduling application. Unfortunately, the TGA decided against our first rescheduling application at the end of 2021.

In 2022, we have again applied for the **rescheduling of medical grade psilocybin and medical grade MDMA** when used as part of therapy in medically controlled environments **from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines)** of the Commonwealth Government’s Standard for the Uniform Scheduling of Medicines and Poisons (often referred to as the Poisons Standard). Rescheduling will open up legislative permit pathways in individual States and Territories around Australia to enable medical practitioners who receive an approval from the TGA to use one of these medicines as part of therapy for a specific patient to also be able to apply for the necessary medical consent from the Government of the State or Territory where they and their patient reside.

Our Progress

- 1

4 March 2022 – Lodgement deadline for scheduling application
- 2

29 April 2022 – Public notice of proposed changes to scheduling and invitation to comment
- 3

27 May 2022 – Public submission deadline
- 4

September 2022 – Public notice of interim decisions and invitation to comment
- 5

October 2022 – Public submission deadline
- 6

November 2022 – Public notice of final decisions

OUR EVENTS

Since our launch, we have had over **200+ webinars, screenings and special events** with renowned international speakers attracting **41,000+ participants**. Our lineup of Australian and international speakers has included MAPS founder **Dr Rick Doblin (USA)**, Psychiatrist **Dr Stanislav Grof (Czech)**, Physician and Author **Dr Gabor Maté (Canada)**, Psychiatrist **Dr Ben Sessa (UK)**, Psychedelics Researcher **Dr Robin Carhart-Harris (UK)** and many more.

In addition to our own educational events, we have also taken part in many education partnership events, such as the ACNEM and Psytech conferences.

Join our free webinar series!

Psychedelic Renaissance? Update on Research and Progress Around the World
With Dr Rick Doblin (USA)

Wednesday 15 June 2022
1:00pm – 2:15pm (AEST)

Join our free webinar series!

A Unified Model for Human Development
With Nigel Denning and Dr Tra-ill Dowie

Wednesday 18 January 2022
7:00pm – 8:15pm (AEDT)

Join our free webinar series!

The Future of Mental Health for Australia's Defence Force Veterans
With Admiral Chris Barrie AC, Dr Stuart Saker, Peter Hunt AM and Michael Raymond

Thursday 5th May 2022
6:00pm – 7:15pm (AEST)

"Thank you so much for making it possible for us to learn all these incredible therapies and practices, and to listen to the leading scientists and doctors in the field...Cutting edge research, new innovative approaches. World famous people. I can go on and on and on! Thank you all for your work!" - Baiba Baika, Germany

Join our free webinar series!

A New Era of Experiential Medicine: Exploring the Interface of Technology, Neuroscience and Psychedelics
With Dr Adam Gazzaley (USA)

Wednesday 1 June 2022
1:00pm – 2:15pm (AEDT)

Join our free webinar series!

Psychedelics in Human Adaptation and Evolution
With Dr Michael Winkelman (Brazil)

Wednesday 20 April 2022
7:30pm – 8:45pm (AEST)

Join our free webinar series!

Shamanism: The Myth of Eden, Psychedelics, and Shame: Our Original Wound
With Dr Alberto Villoldo (USA)

Wednesday 9 March 2022
1:00pm – 2:15pm (AEDT)

INTERNATIONAL SUMMIT 2021

Mind Medicine Australia held a two-day online International Summit on Psychedelic Therapies for Mental Illness in November 2021, which brought together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy makers, business, industry, investors, consumers and other interested stakeholders.

The event also featured a **two-day pre-Summit Introductory Workshop Program** (17-18 November) led by Nigel Denning, Dr Tra-ill Dowie with world-leading therapist trainer Dr Bill Richards (USA) from Johns Hopkins University. It was for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the treatment of mental illness.

The Summit featured a rich program with a mixture of **international and national keynotes, hot spots, panel conversations and Q & A.**

Leading international speakers and Mind Medicine Australia Ambassadors included: **Professor David Nutt (UK)** Head of Neuropsychopharmacology at Imperial College London and Chief Research Officer at Awakn Life Sciences, **Dr Gabor Maté (Canada)** renowned trauma and addiction physician, **Professor Roland Griffiths (USA)** Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, **Dr Bill Richards (USA)** world-leading therapist trainer and psychologist at the Johns Hopkins School of Medicine, **Dr Ben Sessa (UK)** Chief Medical Officer at Awakn Life Sciences, Psychiatrist, Researcher and Writer, **Professor Robin Carhart-Harris (UK)** Ralph Metzner Distinguished Professor, Weill Institute for Neurosciences and University of California San Francisco, **Johann Hari (UK)** Journalist and Bestselling Author, **Francoise Bourzat (USA)** Psychedelic Guide Trainer and Author, **Wade Davis (Canada)** anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society, **Dr Alberto Villoldo (USA)** medical anthropologist and author, **Dr Lynn Marie Morski (USA)** President of the Psychedelic Medicine Association, **Professor Matthew Johnson (USA)** Susan Hill Ward Professor of Psychedelics at Johns Hopkins University School of Medicine, **Dr Rami Batal (USA)** Chief Executive Officer – Universal Ibogaine, **Dr Reid Robinson (USA)** Psychiatrist, Psychedelic Researcher and Chief Medical Officer at Novamind, **Dr Jennifer Mitchell (USA)** Professor in the Departments of Neurology and Psychiatry and Behavioral Sciences at UCSF, **Patrycja Slawuta (USA)** Researcher & Psychologist, **Admiral Chris Barrie AC (AUS)** former Head of the Australian Defence Force and Strategic Leadership Consultant, **Professor Arthur Christopoulos (AUS)** Professor of Analytical Pharmacology and Molecular Neuropsychopharmacologist at Monash University, **Ronan Levy (Canada)** Co-founder and the Executive Chairman of Field Trip Health, **Srinivas Rao (USA)** co-founder & Chief Scientific Officer, atai Life Sciences, **Kelsey Ramsden (Canada)** Co-Founder, CEO & President of Mindcure, **Dr Lyle Oberg (Canada)** Co-Founder and CEO at MYND, **Michael Winlo (AUS)** Managing Director, Emyria, **Joseph Araujo (Canada)** Co-Founder and Chief Scientific Officer of Mindset Pharma and the CEO and President of InterVivo Solutions, **John Skeritt (AUS)** Deputy Secretary, Health Products Regulation Group - TGA, **Dr Simon Longstaff (AUS)** Executive Director of The Ethics Centre, **Dr Eli Kotler (AUS)** Psychiatrist and Director of Medicine at Malvern Private Hospital... and more.

"Never have I attended a conference with such a wealth of knowledge, coupled with wisdom and respect for other cultures and across disciplines." Katharine Clarke, Psychologist, NSW

"Mind blowing, goose bumping, tear inducing in the best possible way!" Casey Harvey, Counsellor, NSW



The summit included a diverse range of national and international keynote and hot spot speakers



From top: Wade Davis (Canada), Dr Alberto Villoldo (USA) and Dr Gabor Maté (Canada) meditating with our audience during the event

NEUROMEDICINES DISCOVERY CENTRE

In November 2021, Monash University announced the establishment of the Neuromedicines Discovery Centre to focus on psychedelic-assisted therapies for the treatment of key classes of mental illness.

We are delighted that Monash University announced the establishment of the Neuromedicines Discovery Centre (NDC) to focus on **psychedelic-assisted therapies for the treatment of mental illness**. This initiative was developed from a proposal put to Monash University by Mind Medicine Australia and our advocacy work with key stakeholders.

“The establishment of the Neuromedicines Discovery Centre follows a proposal put to Monash by Mind Medicine Australia and nearly two year of preparatory work. We are delighted to see the university sector in Australia recognise the paradigm-shifting nature of these therapies and their potential to dramatically reduce the incidence of key classes of mental illness in our society. This Centre can help Australia become a global leader in this field.” - Peter Hunt AM

The NDC is led by **Professor Arthur Christopoulos** and brings together the combined expertise and resources of World leading researchers from **Monash and collaborators from the University of Melbourne, Phoenix Institute and the Florey Institute of Neuroscience and Mental Health**. Unlike other centres overseas working on the development of psychedelic-assisted therapies to treat key classes of mental illness, the NDC spans the entire medicines development pipeline, from drug discovery and optimisation, to clinical trials, new healthcare guidelines and into the public policy area.

As a registered charity, Mind Medicine Australia is focused on developing the ecosystem for the use of psychedelic-assisted therapies in Australia as a treatment option for key classes of mental illness. Our aim is for these therapies to become a normal part of our mental health system so that many more Australians suffering from key classes of mental illness can get well. We aim for these therapies to be affordable to all Australians that need access to them.



“Without courage we cannot practice any other virtue with consistency. We can’t be kind, true, merciful, generous, or honest.”

Maya Angelou

OUR LOCAL CHAPTERS

Mind Medicine Australia’s Chapters are grassroots, community-led groups that operate in a way that is relevant, appropriate and considerate of the context of the local community that surrounds them. Our Chapters aim to build awareness, educate local health practitioners and politicians, cultivate understanding and to fundraise through events and other activities.

Since March 2021, our chapters have **grown from 700 members to over 2200+**. They continued to host successful awareness and fundraising events throughout 2021 both **in person and online**, despite the challenging environment created by the continuing pandemic.

With COVID restrictions coming to an end, MMA’s chapters have gone from strength to strength. In addition to hosting successful public events and advocating with stakeholders to raise the profile of psychedelic-assisted psychotherapies, many chapters have built a strong sense of community with regular chapter catch-ups. We have also begun rolling out an initiative for chapters to set up Mind Medicine Australia market stalls, creating an opportunity for all chapter members to actively raise awareness in their communities.

We are incredibly grateful for the continued support of our chapter members and leaders, partner venues and donors for working with us to engage in meaningful collaboration with local communities and look forward to working together for the remainder of 2022 and beyond.



33+ Chapters in
Australia and New Zealand
with 2200+ Members



Australia:

- Adelaide
- Alice Springs
- Ballarat
- Blue Mountains
- Brisbane
- Bendigo
- Byron Bay
- Cairns
- Canberra
- Castlemaine
- Coffs Harbour
- Curtin University (Perth)
- Darwin
- Dandenong Ranges
- Geelong
- Gold Coast
- Hobart
- Melbourne
- Newcastle
- Orange
- Perth
- Sydney
- Sunshine Coast
- Tamworth
- Wagga Wagga
- Wollongong

New Zealand:

- Auckland
- Christchurch
- Dunedin
- Wellington



OUR VOLUNTEERS

Volunteers are the lifeblood of our organisation. As a not-for-profit organisation, we survive and thrive from the in-kind donations of our community. Although financial contributions are endlessly valuable for us, our volunteers contribute something greater.

In 2021, the support of our volunteers was critical in responding to the challenges and opportunities Mind Medicine Australia faced. With experts from every background and walk of life imaginable, we were able to draw upon knowledge and expertise to deliver a range of extremely high quality outcomes. They supported our second submission to the TGA to reschedule psilocybin and MDMA, provided expert insights and guidance to help direct our strategic efforts, assisted with research projects, copy writing, marketing and social media and even ran a book club.

It is clear that **we wouldn't be where we are today without the extraordinary contributions of our volunteers** and we are continuously grateful and honoured to have their support.


Our non-chapter volunteer team is made up of **over 20 regular and occasional volunteers** from around Australia.

We look forward to continue to work closely with our volunteer supporters in providing them with meaningful ways to interact with our organisation and to help make psychedelic-assisted psychotherapy a reality for our community in 2021.



Curtin University Chapter BBQ in May 2022

OUR BOOK



In October 2021, Mind Medicine Australia released a new book sharing the psychedelic healing stories of 53 Australians, in their own words. Launched during Mental Health Month, this first Australian book of true stories further reinforces the life-changing and life-saving impact of psychedelic-assisted therapies for a range of mental illnesses and addictions.

This book was created to **raise awareness among the general public about the healing potential of psychedelics and to reduce stigma** around their use. It also provides a platform for selected authors to share their experiences of hope and healing, and have their voices heard to advocate for the therapeutic use of psychedelics.

With the help of our extensive Chapter network throughout Australia, **we compiled the stories of 53 Australians**, asking them:

1. What led you to seek healing through psychedelic medicine?
2. What was your psychedelic experience like?
3. How have you been able to integrate this experience?
4. How has it contributed to your healing process?

This book will show you the deeply human side of the effect this medicine can have, and give you hope, inspiration and clarity around what is possible for Australians when we get fair access to these breakthrough medicines. **Available in hard copy or e-book at: shop.mindmedicineaustralia.org**

THE MIND MEDICINE INSTITUTE

A huge milestone last year has been the founding of the Mind Medicine Institute

Mind Medicine Institute is an independent training and consultancy organisation **dedicated to the development of leading edge clinical training** in a wide range of areas connected to mental health. Mind Medicine Institute (MMI) has emerged from the charitable work of Mind Medicine Australia and is dedicated to supporting the betterment of humanity through helping individual minds heal.

Mind Medicine Institute is committed to integrating and exploring new frontiers in clinical practice by drawing together knowledge from a wide range of disciplines such as **psychology, psychiatry, psychotherapy, neuroscience, cognitive science, anthropology, philosophy of mind, and eastern contemplative practices.**


A note from the current Lead Facilitators



"We are excited about the opportunity to partner with Mind Medicine Australia and to take up from the great work already done in putting the potential for working with psychedelic medicine on the map in Australia. Tra-ill and I are committed to developing the educational and clinical application of this work to the highest ethical standards. We are also committed to the development of a world class understanding of the huge potential that psychedelic medicines offer as part of psychotherapy in helping end the psychological suffering of people who have not responded to more traditional approaches. Working with medicinal psychedelics in controlled environment opens up a new paradigm in psychological treatment and we are committed to ensuring that this is done with the utmost of clinical integrity."
- Nigel Denning, MA, MPsyh

"I have spent my entire life working in the field of psychotherapeutic training and clinical delivery and I am extremely excited about working with Mind Medicine Australia to bring my skills and knowledge into the emerging paradigm where the use of psychedelic assisted therapy becomes an accepted part of our mental health system. I am particularly interested in the therapeutic structure of working with non-ordinary states and ways to manage this ethically, scientifically and efficaciously for the many patients that we are confident will benefit from the sensible addition of this newly emerging approach. As a philosopher I am also involved in the theoretical implications of working in non-ordinary states following and expanding on the work of William James and those who followed him."

- Dr Tra-ill Dowie, PH.D



The Mind Medicine Institute offers a range of courses in psychedelic-assisted psychotherapies:



Certificate of Psychedelic-Assisted Therapies

Instrumental to Mind Medicine's mission, the institute is **training 150 clinicians this year alone**, in our world renowned **Certificate of Psychedelic-Assisted Therapies.**

In fact, Prof. David Nutt of Imperial College London described it as *"the best training of its kind in the world"*. It is staffed by an **industry leading international faculty** of pioneers that are **delivering gold standard training protocols** to Australian clinicians.

Fundamentals of Psychedelic-Assisted Therapy

In addition to the above intensive training, we also have the **Fundamentals of Psychedelic-Assisted Therapy** - a 4-week online course that has had **over 320 students in its first year of being launched.**



"I'm a GP working in adolescent mental health. The calibre of the presenters and facilitators has been absolutely amazing and way beyond my expectations. Thank you so much for everything you and Peter are doing to bring these much needed medicines to the Australian mental health system. What you have achieved so far is awe-inspiring." - Dr Phoebe Collyer, GP, NSW

"This weekend was the most rounded professional development I can remember doing – I felt nourished in mind, soul and body. Not usually a networker, I surprised myself by connecting with many people that I am sincerely looking forward to meeting again and hopefully working with in the future. Even though the programme was intense, I feel inspired not exhausted; I think this is because there was such a supportive and empathic group of facilitators and participants." - Dr Ria Leonard, Psychiatrist, NSW

We have a lot of exciting projects coming up next year and you can stay informed on the **Mind Medicine Institute website at mindmedicineinstitute.org.au**

OUR PEOPLE

AMBASSADORS

Dr Rick Doblin (USA)

Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)

Professor David Nutt (UK)

Head of Neuropsychopharmacology at Imperial College London

Professor Roland Griffiths Ph.D

Professor of Psychiatry and Behavioural Sciences at Johns Hopkins School of Medicine

Dr Ben Sessa MD (UK)

Psychiatrist, Researcher & Writer

Dr Bill Richards (USA)

Psychologist in the Center for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine

BOARD OF DIRECTORS

Peter Hunt AM (Chair)

Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women's Community Shelters

Tania de Jong AM (Deputy Chair)

Co-founder Mind Medicine Australia, Founder, Creative Universe, Creativity Australia, The Song Room & Creative Innovation Global

Admiral Chris Barrie AC

Chairman, Fearless - PTSD-Australia New Zealand; Former Chief of the Australian Defence Force.

Professor Jane Burns

Chair of Open Arms, Chair of STREAT and Chair of the Centre for Mental Health, Swinburne University

Dr Eli Kotler

Medical Director at Malvern Private Hospital. Consultant Psychiatrist, Addiction and Trauma expert

Dr Simon Longstaff AO

Director, the Ethics Centre

Mono Ray

CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia

The Hon Andrew Robb AO

Australia's Minister for Trade and Investment (2013-2016); Chair of Asia Link

Nicholas Smedley

Chairman, Respiro Limited

ADVISORY PANEL

Dr Scott T. Aaronson (USA)

Director of Clinical Research Programs, Sheppard Pratt Health System and Adjunct Professor in the Department of Psychiatry, University of Maryland

Dr Tanveer Ahmed

Psychiatrist and Author

Dr Mario Alam

Holistic General Practitioner, Founder of the Reset Retreats Centre and the RESET program

Greg Barns

Barrister, Author & Company Director

Prof Ian E. Brichthope

Director of Nutrition and Environmental Medicine, NIIM

Elizabeth Bryan AM

Company Director

Francoise Bourzat (USA)

Psychedelic Guide Trainer and Author

John Burgos

Teacher and Speaker

Cathy Burke

Speaker, Author, Global Change Maker

Prof Ashley Bush

NHMRC Senior Principal Research Fellow, Director of the Melbourne Dementia Research Centre

Dr David Caldicott

Emergency Medicine Consultant

Prof Robin Carhart-Harris (UK)

Ralph Metzner Distinguished Professor, Weill Institute for Neurosciences and University of California San Francisco

Dr Ted Cassidy

Psychiatrist and Co-Founder of TMS Australia

Rita Chowdhury

Lawyer

Prof Arthur Christopoulos

Dean, Faculty of Pharmacy & Pharmaceutical Sciences, Monash University

Bruce Clarke

Chairman, Allygroup Pty Ltd

Dr Wade Davis CM (Canada)

Anthropologist and writer

Dr Dan Engle (USA)

Psychiatrist

Wesley Enoch AM

Writer and Director

Dr James Fadiman (USA)

Psychologist and Author

Robert Falconer (USA)

IFS Practitioner

Amanda Feilding (UK)

Founder and Executive Director of the Beckley Foundation

Prof Paul Fitzgerald

Director at ANU School of Medicine and Psychology and Director of the Epworth Centre for Innovation in Mental Health

Prof David Forbes

Psychologist and Director of Phoenix Australia

Prof Ian Freckelton QC

Queen's Counsel and Supreme Court Judge of Nauru

Prof Paul Frijters (UK)

Research Fellow London School of Economics

Prof Dr Karl J. Friston (UK)

Scientific Director: Wellcome Centre for Human Neuroimaging and Professor: Queen Square Institute of Neurology

Dr Albert Garcia-Romeu (USA)

A/Professor Johns Hopkins University School of Medicine

Dr David Gaskell

Medical Director and Rural Generalist

Dr Suzy Green

Clinical and Coaching Psychologist (MAPS) and Founder and CEO of The Positivity Institute

Dr George Halasz

Consultant Child and Adolescent Psychiatrist and Adjunct Senior Lecturer, Monash University

David Heilpern

Dean of Law at Southern Cross University

Prof Gregg Henriques (USA)

Clinical Psychologist at James Madison University

Prof Malcolm Hopwood

Ramsay Health Care Professor of Psychiatry, University of Melbourne

Tommy Huppert

Founder and CEO of Cannatrek Limited

Prof Matthew W. Johnson (USA)

Susan Hill Ward Professor of Psychedelics at Johns Hopkins University School of Medicine

Mark Joiner

Business Strategist, Non-Executive Director and Finance Executive

Dr Linda Kader

Psychiatrist and Senior Lecturer at the Department of Psychiatry, University of Melbourne

Rabbi Jeffrey Kamins OAM

Rabbinic Advisor and Founder at Voiceless

Helen Kapalos

Journalist, Filmmaker and Advocate

Michael Kornhauser

Pharmaceutical and Clinical Trial Research Specialist

Scott Leckie

International Human Rights Lawyer

Dr Jennifer Loughman

General Practitioner and Entrepreneur

Pastor Graham Long AM

Former Pastor at The Wayside Chapel, Sydney

Dr Paul MacLeman

Corporate Advisor

Dr Sam Manger

General Practitioner, Senior Lecturer and Academic Lead in Lifestyle Medicine, James Cook University College of Medicine

Dr Gabor Maté CM (Canada)

Physician and Author

Prof Rob Moodie AM

Professor of Public Health, University of Melbourne and Adviser to WHO

Dr David E. Nichols (USA)

Psychedelic Chemist and Adjunct Professor, University of North Carolina

Prof Dr Kylie O'Brien

Adjunct Professor, Torrens University, South Australia

Dr Thomas Pogge (USA)

Philosopher and Professor of Philosophy and International Affairs, Yale

Nigel Pollard

Medicine Business Specialist and Chair at Natural Health Science Foundation

Dr David Reiner

Specialist Anaesthesiologist at The Canberra Hospital

Dr Reid Robison (USA)

Psychiatrist, Researcher & Chief Medical Officer, Novamind

Dr Arne Rubinstein

Founder & CEO, The Rites of Passage Institute

Dr James Rucker (UK)

Consultant Psychiatrist & Senior Clinical Lecturer, King's College London

Dr Mark Ryan
Psychiatrist

Dr Stuart Saker
General Adult Psychiatrist with an interest in Veterans' Mental Health

Prof Avni Sali AM
Physician, Founding Director of National Institute of Integrative Medicine and Member of the Scientific Board of The European Congress for Integrative Medicine

Janine Shepherd AM
Speaker and Author, Disability Advocate

Dr Ronald D. Siegel (USA)
Assistant Professor of Psychology, Harvard Medical School

Dr Patrycja Slawuta (USA)
Behavioural Scientist and Founder at SelfHackathon

Dr James Stewart
GP, Cannabinoid Clinician, Doctor of the Year and Peoples Choice Award at the National Cannabis Industry Awards

Prof Margaret Somerville
Bioethicist at University of Notre Dame Australia

Dr Jack Springer (USA)
Emergency Physician

Imam Tawhidi
Islamic Scholar, Educator, Author, Global Speaker and Vice President of The Global Imams Council

Prof John Tiller
Professor Emeritus of Psychiatry, University of Melbourne

Dr Gita Vaid (USA)
Psychiatrist, Psychoanalyst and Co-Founder at Center for Natural Intelligence

Dr Alberto Villoldo (USA)
Founder the Four Winds Society, Director the Center for Energy Medicine (Chile)

Dr Ross Walker
Consultant Cardiologist, Media Commentator and Advisor

Dr Jeremy Weate
Chief Executive Officer, Eastra Health

Dr Michael Winkelman (USA)
Leader in neurotheological perspectives on shamanism, traditional healing practices, and altered states of consciousness

Dr Alex Wodak AM
Physician, Director of Australia 21 and President of the Australian Drug Law Reform Foundation

Rabbi Dr Laibl Wolf
Dean and Founder of the Spiritgrow Wellness Centre, Melbourne Australia

EXECUTIVE TEAM

Tania de Jong AM
Executive Director

Gavin Abeyratne
Chief Marketing Officer (CMO)

Ilan Hayman
Operations Manager

Scott Edwards
Chapter and Community Manager

Nicole Hearnden
Events and Partnership Manager

Julia Neubauer
Digital Communications, Design and Social Media Consultant

Anthony Licciardi
Education, Program and Administration Coordinator

Katie Stokoe
Chapter Engagement Officer

Brenda Turner
Bookkeeper

Carey Handfield
Bookkeeper

MAJOR INDIVIDUAL SUPPORTERS

Antony de Jong
Andrew Larsen
Paul Cave
Stephen Grant and Sue Petruszka
Lewis Gale
Mark Joiner
Michael Norster
Nicholas Smedley
Ray Wilson and Plenary Group
Steve Grimley

Dr Bronner's
Earth Heroes
Elektra Magnesium
Farmers Daughter Restaurant
Green Leaf Cosmetics
Green Press
Highbration
Murchisons
Pana Chocolate
Sunshine Community Coffee
SuperFeast
Sofitel Melbourne On Collins
Three Pillars

TRUST AND FOUNDATION SUPPORTERS

G G Aviation Pty Limited (Tony Shields)
Hunt Family Foundation
Laser Image Pty Ltd
Sofia Foundation Pty Ltd ATF
The L & R Uechtritz Foundation
Veith Foundation

IN-KIND SUPPORTERS

APOC
Aus Vitality
BEKL and Eva Liu
Bloom Journals
Byron Theatre
Creative Universe
Creative Innovation Global
Cromitol®
Dimension5

“I felt like I went through 15 years of psychological therapy in one night.”
– Patient featured in Trip of Compassion

Meetings of Directors

During the period covered by this Review, there were 3 Board Meetings of Directors. Attendances by each Director during the period were as follows:

Board member	Number eligible to attend	Number attended
Peter Hunt AM	3	3
Tania de Jong AM	3	3
Admiral Chris Barrie AC	3	3
Professor Jane Burns	3	3
Dr Eli Kotler	3	2
Dr Simon Longstaff	3	3
Monojit (Mono) Ray	3	3
Hon Andrew Robb AO	3	3
Nicholas Smedley	3	3

Company particulars

Mind Medicine Australia Limited
ABN: 62 630 150 873
Level 1, 10 Dorcas Street
South Melbourne VIC 3205

Mind Medicine Australia Limited is a company limited by guarantee, incorporated in Australia and having its principal place of business at the address listed above.

The charity has deductible gift recipient (DGR) status; all donations are tax-deductible.

Mind Medicine Australia
ABN 62 630 150 873
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2021

	Note	2021	2020
		\$	\$
Conference Income		100,071	72,459
Consulting Patients Income		66,623	-
CPAT – fees Income		249,501	-
Donations - Corporate		97,500	-
Donations - Events		60,761	39,918
Donations - Individuals		297,339	65,040
Donations - Trusts and Foundations		330,271	401,207
Other Income		149,546	48,120
Gross Profit		1,351,612	626,744
Interest Income		25	46
		1,351,637	626,790
Consulting and Professional fees		(245,556)	(136,395)
CPAT Course expenses		(102,848)	-
Donations		-	(54,647)
Employee benefits		(361,044)	(220,368)
Other expenses		(254,553)	(144,712)
Rent		(37,637)	(24,314)
Research		(52,000)	-
Finance costs		(2,252)	(3,168)
Total Expenses		(1,055,890)	(583,604)
Profit before income tax		295,747	43,186
Income tax expense		-	-
Net Profit		295,747	43,186
Other comprehensive income:			-
Total comprehensive income for the year		295,747	43,186

Mind Medicine Australia
ABN 62 630 150 873
STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2021

	Note	2021 \$	2020 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	4	842,141	294,830
Accounts Receivable	5	208,004	3,795
TOTAL CURRENT ASSETS		1,050,145	298,625
NON-CURRENT ASSETS			
Other assets	6	5,598	7,578
TOTAL NON-CURRENT ASSETS		5,598	7,578
TOTAL ASSETS		1,055,743	306,203
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	7	107,460	56,924
Employee provisions	8	7,397	6,930
Deposits	9	551,412	148,622
TOTAL CURRENT LIABILITIES		666,269	212,476
TOTAL LIABILITIES		666,269	212,476
NET ASSETS		389,474	93,727
EQUITY			
Retained earnings	10	389,474	93,727
TOTAL EQUITY		389,474	93,727

Mind Medicine Australia
ABN 62 630 150 873
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2021

	Note	Retained Earnings \$	Total \$
Balance at 1 July 2019		50,541	50,541
Comprehensive income			
Profit for the year		43,186	43,186
Other comprehensive income for the year		-	-
Total comprehensive income		93,727	93,727
Balance at 30 June 2020		93,727	93,727
Comprehensive income			
Profit for the year		295,747	295,747
Other comprehensive income for the year		-	-
Total comprehensive income		295,747	295,747
Balance at 30 June 2021		389,474	389,474

Mind Medicine Australia
ABN 62 630 150 873
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2021

	Note	2021 \$	2020 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		764,322	116,785
Payments to suppliers and employees		(1,002,907)	(532,201)
Interest received		25	46
Donations received		785,871	654,787
Net cash provided by operating activities	12	<u>547,311</u>	<u>239,417</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Net proceeds from / (repayment of) borrowings		-	1,414
Net cash provided by / (used in) financing activities		<u>-</u>	<u>1,414</u>
Net (decrease)/increase in cash and cash equivalents held		547,311	240,831
Cash at beginning of the financial year		294,830	53,999
Cash at end of the financial year	4	<u>842,141</u>	<u>294,830</u>



*"No society can understand itself
without looking at its shadow side."*

Dr Gabor Maté

Mind Medicine Australia
Level 1, 10 Dorcas Street
South Melbourne VIC 3205, Australia

Phone: (03) 8679 6015
hello@mindmedicineaustralia.org
www.mindmedicineaustralia.org